# Retraction: Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway

## TL;DR

This paper is a retraction of a previous study that claimed Astragaloside IV reduces liver cancer aggression through a specific signaling pathway.

## Contribution

The retraction highlights the correction or removal of previously published findings on Astragaloside IV's effect on hepatocellular carcinoma.

## Key findings

- The original study's claims about Astragaloside IV's impact on liver cancer were retracted.
- The retraction suggests potential issues with the validity of the original research findings.

## Abstract

Retraction of ‘Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway’ by ZhongYu Jiang et al., RSC Adv., 2019, 9, 35473–35482, https://doi.org/10.1039/C9RA05933D.